Pichon MF - Search Results

1

Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours.

Pallud C, Guinebretiere JM, Guepratte S, Hacene K, Neumann R, Carney W, Pichon MF. Pallud C, et al. Among authors: pichon mf. Anticancer Res. 2005 Mar-Apr;25(2B):1433-40. Anticancer Res. 2005. PMID: 15865102 Free article.

2

Serum HER-2 extracellular domain (ECD) before the first metastasis in 128 breast cancer patients.

Pichon MF, Hacene K, Guepratte S, Neumann R. Pichon MF, et al. Clin Lab. 2004;50(3-4):163-70. Clin Lab. 2004. PMID: 15074470

3

Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients.

Bethune-Volters A, Labroquere M, Guepratte S, Hacene K, Neumann R, Carney W, Pichon MF. Bethune-Volters A, et al. Among authors: pichon mf. Anticancer Res. 2004 Mar-Apr;24(2C):1083-9. Anticancer Res. 2004. PMID: 15154627 Free article.

4

Immunohistochemistry of pS2 in normal human breast and in various histological forms of breast tumours.

Pallud C, Le Doussal V, Pichon MF, Prud'homme JF, Hacene K, Milgrom E. Pallud C, et al. Among authors: pichon mf. Histopathology. 1993 Sep;23(3):249-56. doi: 10.1111/j.1365-2559.1993.tb01197.x. Histopathology. 1993. PMID: 8225243

5

Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients.

Pichon MF, Moulin G, Pallud C, Pecking A, Floiras JL. Pichon MF, et al. Anticancer Res. 2000 Mar-Apr;20(2B):1189-94. Anticancer Res. 2000. PMID: 10810420

6

Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients.

Saghatchian M, Guepratte S, Hacene K, Neumann R, Floiras JL, Pichon MF. Saghatchian M, et al. Among authors: pichon mf. Int J Biol Markers. 2004 Jan-Mar;19(1):14-22. doi: 10.1177/172460080401900102. Int J Biol Markers. 2004. PMID: 15077922 Free article.

7

Comparison of fifteen immunoassays for the measurement of serum MUC-1/CA 15-3 in breast cancer patients.

Pichon MF, Brun GL, Hacene K, Basuyau JP, Riedinger JM, Eche N, Fulla Y, Charlier-Bret N. Pichon MF, et al. Clin Chem Lab Med. 2009;47(8):985-92. doi: 10.1515/CCLM.2009.213. Clin Chem Lab Med. 2009. PMID: 19548847

8

Prognostic value of CA 15.3 kinetics for metastatic breast cancer.

De La Lande B, Hacene K, Floiras JL, Alatrakchi N, Pichon MF. De La Lande B, et al. Among authors: pichon mf. Int J Biol Markers. 2002 Oct-Dec;17(4):231-8. doi: 10.1177/172460080201700403. Int J Biol Markers. 2002. PMID: 12521126 Free article.

9

Comparison of Cyfra 21-1 and SCC assays in head and neck tumours.

Banal A, Hacene K, Berthelot-Ruff E, Mahé E, Fontana X, Pichon MF. Banal A, et al. Among authors: pichon mf. Tumour Biol. 2001 Jan-Feb;22(1):27-35. doi: 10.1159/000030152. Tumour Biol. 2001. PMID: 11054024

10

Prognostic value of progesterone receptor after long-term follow-up in primary breast cancer.

Pichon MF, Pallud C, Hacene K, Milgrom E. Pichon MF, et al. Eur J Cancer. 1992;28A(10):1676-80. doi: 10.1016/0959-8049(92)90067-c. Eur J Cancer. 1992. PMID: 1389484

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

52 results

Search Page

Filters